Technology I
Multiplex Genome Editing Platform
Pioneer in Genome Editing
Pioneer in Genome Editing
Pioneered the new generation of gene-editing technology, CRISPR, and demonstrated for the first time that genome editing is possible in human and other mammalian cells
Record-breaking Multiplexable Gene Knock Out
Record-breaking Multiplexable Gene Knock Out
62 genes in a single cell were successfully knocked out with the gene-editing tool
Programmable Multiplexable Transgene Expression
Programmable Multiplexable Transgene Expression
Multiple transgenes Knock-in and ensure durable in vivo expression
Immune-privileged Multiplexable Genome Modifications
Immune-privileged Multiplexable Genome Modifications
To engineer immune-privileged cells and large-scale genome edits to create universal cell and organ donors
Technology II
Immune Privilege Platform
Qihan’s unique “immune-privileged” cell and organ platform, stemming from our advanced genome engineering technologies and deep understanding of transplantation immunology, enables us to produce next-generation cells and organs that can evade immune attacks. We strive to engineer human cells and tissues for allogeneic applications such as Natural Killer cells for immune oncology, as well as cardiomyocytes, neurons and islet cells for regenerative medicine. We also pioneer in engineering extensively genome-modified pigs as bioreactors to “grow” xenogeneic cells, tissues and organs for safe and effective clinical applications.
Macrophage
T Cell
Antibody
NK Cell
B Cell
Inflammatory Cell
Immune Attack
Products
Common Platform Giving Rise to Multiple Products
ORGANS
CELLS
Kidney
Intestine
Heart
Lung
Liver
Skin
Islet cells
Cardiomyocytes
Neurons
Immune cells
Products
Other applications
Besides cell and organ therapies, we also apply our multiplex genome-editing technology to other applications, such as producing animals with enhanced agronomical traits or multi-disease resistance in agriculture.